- Fresenius Medical Care reported an operating income excluding special items of €457 million, marking a 13% increase year-on-year.
- The company’s revenue reached €4.88 billion, experiencing a 3.3% growth compared to the previous year.
- Operating income surged to €331 million, a 35% rise from the previous year.
- Net income significantly increased to €151 million, compared to €71 million from the same period last year.
- Excluding special items, net income grew by 31% to €246 million.
- Basic earnings per share (EPS) increased from €0.24 to €0.52 year-on-year.
- Excluding special items, basic EPS rose from €0.64 to €0.84 compared to the previous year.
- Fresenius Medical Care maintains a positive outlook for fiscal 2025, expecting revenue growth in the low-single-digit percentage range.
- The company anticipates operating income excluding special items to grow in the high-teens to high-twenties percent rate for 2025.
- The portfolio optimization plan completed in 2024 is projected to reduce the full-year 2025 group revenue growth by approximately 1%.
A look at Fresenius Medical Care & Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 4 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Analysts utilizing the Smartkarma Smart Scores have provided a positive long-term outlook for Fresenius Medical Care AG & Co. KGaA. With impressive scores of 4 in both Value and Dividend, and scores of 3 in Growth and Resilience, along with a Momentum score of 4, the company is seen favorably across key metrics. Fresenius Medical Care offers kidney dialysis services, manufactures dialysis equipment, conducts clinical laboratory testing, and provides various healthcare services globally.
The overall assessment of Fresenius Medical Care based on the Smartkarma Smart Scores indicates a robust outlook for the company. With strong ratings in Value, Dividend, Momentum, and a solid performance in Growth and Resilience, analysts are optimistic about the company’s future prospects. Fresenius Medical Care’s diverse range of healthcare services and global presence position it well for long-term growth and stability in the industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
